Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
13.5.2021 13:00:00 EEST | Business Wire | Press release
Knopp Biosciences LLC today announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference.
“We look forward to sharing comprehensive results of the EXHALE trial, which underscore the readiness of dexpramipexole for further development in eosinophilic asthma,” said Michael Bozik, M.D., president and CEO of Knopp. “Monoclonal antibody treatments approved for asthma demonstrate that reduction in eosinophils is associated with significantly improved outcomes, but the need remains for an oral alternative in the eosinophilic asthma treatment paradigm.”
Following are details of the poster presentation:
|
Poster Title |
Abstract Number / Presentation Details |
|
|
Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma
|
A1359 Poster Presentation
Presenter: Calman Prussin, M.D., VP, Clinical and Translational Medicine, Knopp Biosciences LLC
Time: 8 a.m. EDT
|
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with conference news and updates using the hashtag #ATS2021.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus. Please visit www.knoppbio.com.
ABOUT DEXPRAMIPEXOLE
Dexpramipexole, a selective inhibitor of eosinophil maturation, is an oral small molecule drug in development by Knopp for asthma and other eosinophil-associated diseases. In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission. In its earlier development in amyotrophic lateral sclerosis, dexpramipexole was shown to be well tolerated in Phase 1, Phase 2, and Phase 3 trials comprising approximately 1,200 patients.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events, or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.
Media inquiries:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005183/en/
Contact information
Tom Petzinger
tom@knoppbio.com
412-488-1776
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Advances Satellite Manufacturing Facility in Luxembourg24.9.2026 09:50:00 EEST | Press release
SES, a space solutions company, has commenced construction of a new satellite manufacturing facility in Kockelscheuer, Luxembourg, marking a major milestone in the company’s vertical integration and business model evolution. The facility will enhance SES’ ability to design, develop and manufacture critical satellite technologies, accelerating the deployment of next-generation satellite networks and secure communications solutions. It will also help create a hub for innovation and enable SES partners and ecosystem with opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923560183/en/ SES Advances Satellite Manufacturing Facility in Luxembourg The new facility in Kockelscheuer is at the center of Luxembourg’s effort to build and scale a dedicated Space Campus to stimulate New Space companies and industrial collaboration, and serve as a center for engineering, testing, manufacturing and assembly, accelerating devel
NTT DOCOMO BUSINESS Launches “Pro”, a New docomo business SIGN ® Offering for Large-Scale Global Connected Products24.9.2026 05:00:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) announced today the launch of "Pro," a new offering in the docomo business SIGN®1 lineup, an IoT-focused Network as a Service (NaaS) with built-in security features. Designed to support the large-scale and global deployment of connected products, “Pro” helps customers manage and operate tens of thousands of IoT connections. The service will be available from March 2027. This new offering addresses the challenges of achieving more advanced operational management through the centralized management of domestic and international IoT connectivity, operational automation, and system integration, while also enhancing security. It will reduce the operational burden on customers while supporting the continued delivery of value through connected products and services. 1. Background In recent years, against the backdrop of labor shortages resulting from Japan’s declining birthrate and aging population, various industries, such as
HeadFirst Global Becomes Vertage, Uniting 11 Businesses in a Single Work Orchestration Platform24.9.2026 02:01:00 EEST | Press release
HeadFirst Global, a leader in work orchestration, today announced it will become Vertage, as it builds a global technology platform that dynamically curates the right mix of expert talent and AI agents to deliver the work outcomes enterprises need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923823506/en/ Edzard Overbeek, Group CEO at Vertage The €10 billion group is bringing its 11 operating businesses together under the Vertage name, platform, and operating model. Vertage starts with a foundation few can match: 1.5 million specialists, more than €10 billion in gross invoice value from multi-sector enterprise customers and governments, and delivery across 80 countries. The capabilities come from the 2024 integration of HeadFirst Group and Impellam Group, which combined technology and data with leadership in global managed services and specialist talent communities, and from the group's subsequent expansion into India.
Grid Dynamics Co-Hosts Physical AI Summit Alongside NVIDIA, EAIGG, and BGV to Accelerate Manufacturing Automation23.9.2026 23:05:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, announced today that it is co-hosting the Physical AI Summit alongside NVIDIA, EAIGG, and BGV. The invite-only working forum will bring together participants from enterprises, Physical AI startups, and investors on September 24, 2026, at the Wells Fargo Innovation Center in Menlo Park, CA. Centered on the theme "From World Models to Real-World Control," the summit will focus on the practical challenges of deploying, scaling, and operating Physical AI systems in production. Grid Dynamics' participation builds on its strategic partnerships with NVIDIA and Doosan Robotics, expanding its Physical AI capabilities to advance enterprise robotics applications. Ilya Katsov, CTO, Americas at Grid Dynamics, will lead a session titled "Operationalizing Physical AI: Lessons From the Field." The session will draw on Grid Dynamics' experience deploying Physical AI, including humano
Liquid AI, in Collaboration with Qualcomm Technologies, Brings Personal AI Context to Devices Powered by Snapdragon23.9.2026 22:00:00 EEST | Press release
Liquid AI today, at Snapdragon Summit 2026, announced that Liquid Context, an on-device context layer, is now optimized for Snapdragon® processors, specifically using the Qualcomm® Hexagon™ NPU. In collaboration with Qualcomm Technologies, Liquid Context built a persistent understanding of the user from signals from devices with Snapdragon processors and made relevant context available to AI agents, whether they ran on the device, in the cloud or across both. Device manufacturers now have a foundation for more proactive, personalized and trustworthy AI experiences, alongside Liquid Agent, Liquid AI’s efficient embedded agent. Personal Context That Makes Any Agent More Useful Useful agents need to understand what matters to the user and when help is needed. With the user’s permission, Liquid Context learns from device signals, builds an understanding of routines, preferences and needs, and keeps that understanding current. It provides a shared context layer between the device and the us
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom